JP2012520883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520883A5 JP2012520883A5 JP2012500854A JP2012500854A JP2012520883A5 JP 2012520883 A5 JP2012520883 A5 JP 2012520883A5 JP 2012500854 A JP2012500854 A JP 2012500854A JP 2012500854 A JP2012500854 A JP 2012500854A JP 2012520883 A5 JP2012520883 A5 JP 2012520883A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- agent
- composition
- serotonin
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 6
- WFZKRNIMSVDNBU-UHFFFAOYSA-N Creatinine sulfate mixture with serotonin Chemical compound [O-]S([O-])(=O)=O.C[NH+]1CC(=O)N=C1N.C1=C(O)C=C2C(CC[NH3+])=CNC2=C1 WFZKRNIMSVDNBU-UHFFFAOYSA-N 0.000 claims 5
- 229960004329 metformin hydrochloride Drugs 0.000 claims 5
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims 5
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical group O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims 2
- 229960004111 buformin Drugs 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 2
- 229960003243 phenformin Drugs 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- BYNFKPVCVMZGOI-UHFFFAOYSA-N 3-(2-aminoethyl)-1h-indol-5-ol;sulfuric acid Chemical compound OS([O-])(=O)=O.C1=C(O)C=C2C(CC[NH3+])=CNC2=C1 BYNFKPVCVMZGOI-UHFFFAOYSA-N 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- MDIGAZPGKJFIAH-UHFFFAOYSA-N Serotonin hydrochloride Chemical compound Cl.C1=C(O)C=C2C(CCN)=CNC2=C1 MDIGAZPGKJFIAH-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 1
- 229950006790 adenosine phosphate Drugs 0.000 claims 1
- 208000020450 carbohydrate metabolism disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- 230000002431 foraging effect Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000017745 inborn carbohydrate metabolic disease Diseases 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000002555 ionophore Substances 0.000 claims 1
- 230000000236 ionophoric effect Effects 0.000 claims 1
- 229960000965 nimesulide Drugs 0.000 claims 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 1
- 230000010627 oxidative phosphorylation Effects 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 239000002342 ribonucleoside Substances 0.000 claims 1
- WKEDVNSFRWHDNR-UHFFFAOYSA-N salicylanilide Chemical compound OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 claims 1
- 229950000975 salicylanilide Drugs 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229940026197 serotonin hydrochloride Drugs 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 229940034208 thyroxine Drugs 0.000 claims 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16053309P | 2009-03-16 | 2009-03-16 | |
| US61/160,533 | 2009-03-16 | ||
| PCT/US2010/027330 WO2010107702A1 (en) | 2009-03-16 | 2010-03-15 | Treating alzheimer's disease and osteoporosis and reducing aging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012520883A JP2012520883A (ja) | 2012-09-10 |
| JP2012520883A5 true JP2012520883A5 (OSRAM) | 2013-05-02 |
Family
ID=42731206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500854A Pending JP2012520883A (ja) | 2009-03-16 | 2010-03-15 | アルツハイマー病及び骨粗鬆症の治療並びに老化の軽減 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8377947B2 (OSRAM) |
| EP (1) | EP2408434A4 (OSRAM) |
| JP (1) | JP2012520883A (OSRAM) |
| CN (1) | CN102395359A (OSRAM) |
| AU (1) | AU2010225923B2 (OSRAM) |
| WO (1) | WO2010107702A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US8980132B2 (en) * | 2010-02-12 | 2015-03-17 | Ocean's King Lighting Science & Technology Co., Ltd. | Borosilicate luminescent material and preparing method thereof |
| EP2911664B1 (en) | 2012-10-25 | 2019-05-08 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| WO2014143125A1 (en) * | 2013-03-13 | 2014-09-18 | Alevere Medical Corporation | Use of indole compounds for fat reduction and skin and soft tissue tightening |
| CN118105365A (zh) | 2013-03-15 | 2024-05-31 | 马斯公司 | 化合物在制备预防或治疗伴侣动物的特发性呕吐的药物中的用途 |
| CA2903907C (en) | 2013-03-15 | 2022-10-18 | The Iams Company | Composition and method for preventing, reducing, alleviating or treating idiopathic vomiting |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| US20150086616A1 (en) * | 2013-09-20 | 2015-03-26 | Steven Lehrer | Method for the prevention and treatment of alzheimer's disease |
| AU2014340351B2 (en) | 2013-10-21 | 2020-01-30 | Alevere Medical Corporation | Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof |
| US10188757B2 (en) * | 2013-10-22 | 2019-01-29 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| KR101743960B1 (ko) * | 2015-07-06 | 2017-06-08 | 서울대학교산학협력단 | G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물 |
| CN109195589A (zh) | 2016-03-07 | 2019-01-11 | 米托充制药公司 | 神经肌肉性、神经变性、自身免疫性、发育性、脑震荡、干眼病和/或代谢性疾病的dnp和dnp前药治疗 |
| US20190240194A1 (en) | 2016-08-31 | 2019-08-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| MX2020000577A (es) | 2017-07-20 | 2020-09-10 | Aztherapies Inc | Formulaciones en polvo de cromolina sodica e ibuprofeno. |
| WO2020010049A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | POWDERED FORMULATIONS OF CROMOLYN SODIUM AND α-LACTOSE |
| CN113727736A (zh) | 2018-12-10 | 2021-11-30 | 通用医疗公司 | 色甘酸酯及其用途 |
| KR102145438B1 (ko) * | 2018-12-21 | 2020-08-18 | 연세대학교 산학협력단 | 퇴행성 뇌질환 발병 위험성 예측용 조성물 및 이를 이용한 퇴행성 뇌질환의 발병 위험성 예측 방법 |
| WO2021029434A1 (ja) * | 2019-08-15 | 2021-02-18 | 賢 石井 | 首下がり症候群および胸腰椎脊柱変形の治療薬 |
| JP2023520580A (ja) | 2020-04-06 | 2023-05-17 | ザ ジェネラル ホスピタル コーポレイション | コロナウイルス誘発炎症状態の処置方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5100919A (en) | 1984-03-19 | 1992-03-31 | The Rockefeller University | Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein |
| EP0284612B1 (en) * | 1986-01-30 | 1991-07-24 | University of Utah | Treatment of bone loss |
| US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
| US5096712A (en) * | 1990-03-06 | 1992-03-17 | Interneuron Pharmaceuticals, Inc. | Method for enhancing performance so as to improve vigor and decrease fatigue, confusion, tension, and anxiety |
| US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| GB9311132D0 (en) | 1993-05-28 | 1993-07-14 | Eisai London Res Lab Ltd | Control of cell death |
| EP0692252B1 (en) | 1994-06-14 | 2001-04-04 | "Raffinerie Tirlemontoise", société anonyme: | Use of a composition containing inulin or oligofructose in cancer treatment |
| US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| AU3641597A (en) * | 1996-06-21 | 1998-01-07 | Advanced Research And Technology Institute, Inc. | Methods and compositions comprising r-ibuprofen |
| US5985930A (en) * | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
| US5776431A (en) * | 1997-03-26 | 1998-07-07 | Galat; Alexander | Water-soluble aspirin composition |
| US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| US20040053900A1 (en) | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
| US6589944B1 (en) | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
| CA2371391A1 (en) * | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| US6495538B2 (en) * | 1999-06-23 | 2002-12-17 | Zinc Therapeutics, Canada Inc. | Zinc ionophores as therapeutic agents |
| US6670330B1 (en) | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
| US6927223B1 (en) | 2000-05-26 | 2005-08-09 | Washington State University Research Foundation | Use of serotonin agents for adjunct therapy in the treatment of cancer |
| NZ524519A (en) | 2000-08-07 | 2004-09-24 | Ranbaxy Signature Llc | Liquid formulation of metformin |
| WO2002038141A2 (en) | 2000-11-08 | 2002-05-16 | Massachusetts Institute Of Technology | Compositions and methods for treatment of mild cognitive impairment |
| US20020137787A1 (en) | 2001-03-21 | 2002-09-26 | Geho W. Blair | Prevention or treatment of complications related to non-insulin dependent diabetes mellitus or type 2 diabetes mellitus |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| EP1534273A4 (en) | 2002-07-18 | 2007-08-22 | Bristol Myers Squibb Co | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD |
| US7674482B2 (en) * | 2002-08-27 | 2010-03-09 | Targeted Medical Pharma Inc. | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods |
| US20060147947A1 (en) | 2002-12-04 | 2006-07-06 | Javier Apfeld | AMPK pathway components |
| US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
| US7329638B2 (en) | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
| AU2003249492A1 (en) | 2003-07-24 | 2005-02-14 | Eswaran Krishnan Iyer | Oral compositions for treatment of diseases |
| US20050054731A1 (en) | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
| US20080194019A1 (en) | 2003-09-09 | 2008-08-14 | Beth Israel Deaconess Medical Center, Inc. | Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase |
| US7244843B2 (en) | 2003-10-07 | 2007-07-17 | Bristol-Myers Squibb Company | Modulators of serotonin receptors |
| US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| BRPI0512856A (pt) | 2004-06-30 | 2008-04-08 | Combinatorx Inc | métodos e reagentes para o tratamento de distúrbios metabólicos |
| WO2006021008A2 (en) | 2004-08-20 | 2006-02-23 | Lind Stuart E | Ionophores as cancer chemotherapeutic agents |
| US20070292478A1 (en) | 2004-08-30 | 2007-12-20 | Popowski Youri | Medical Implant Provided with Inhibitors of Atp Synthesis |
| US20070105790A1 (en) | 2004-09-02 | 2007-05-10 | Bionaut Pharmaceuticals, Inc. | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors |
| JP4745764B2 (ja) * | 2004-09-09 | 2011-08-10 | 花王株式会社 | Ａｍｐｋ活性化剤 |
| AU2005299808B2 (en) * | 2004-10-25 | 2009-08-20 | Novartis Ag | Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin |
| WO2006078698A1 (en) | 2005-01-19 | 2006-07-27 | Cengent Therapeutics, Inc. | 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases |
| JP2008528510A (ja) | 2005-01-20 | 2008-07-31 | サートリス ファーマシューティカルズ， インコーポレイテッド | 紅潮および／または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用 |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| CN101257897A (zh) * | 2005-07-07 | 2008-09-03 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
| CA2614664A1 (en) | 2005-07-14 | 2007-01-25 | Franco Folli | Daily dosage regimen for treating diabetes, obesity,metabolic syndrome and polycystic ovary syndrome |
| US20070054965A1 (en) * | 2005-09-05 | 2007-03-08 | Kao Corporation | AMPK activating agent |
| WO2007047575A2 (en) * | 2005-10-14 | 2007-04-26 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep-related breathing disorders |
| ES2984297T3 (es) * | 2006-01-05 | 2024-10-29 | Essentialis Inc | Sales de abertura de canales ATP de potasio y usos de las mismas |
| AU2007204755A1 (en) | 2006-01-10 | 2007-07-19 | Eugene J. Van Scott | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use |
| AU2007204410A1 (en) | 2006-01-12 | 2007-07-19 | Novartis Ag | Combination of mTOR inhibitor and antipolate compound |
| US7659281B2 (en) | 2006-04-25 | 2010-02-09 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors |
| CN1947719A (zh) * | 2006-10-29 | 2007-04-18 | 广东医学院 | 阿司匹林在防治骨质疏松症的应用 |
| TWI629058B (zh) * | 2007-01-16 | 2018-07-11 | 陳建宏 | 醫藥組成物及其用途 |
| CA2666036C (en) | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
-
2010
- 2010-03-15 AU AU2010225923A patent/AU2010225923B2/en not_active Ceased
- 2010-03-15 CN CN2010800171927A patent/CN102395359A/zh active Pending
- 2010-03-15 EP EP10753934.8A patent/EP2408434A4/en not_active Withdrawn
- 2010-03-15 WO PCT/US2010/027330 patent/WO2010107702A1/en not_active Ceased
- 2010-03-15 US US12/723,771 patent/US8377947B2/en not_active Expired - Fee Related
- 2010-03-15 JP JP2012500854A patent/JP2012520883A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520883A5 (OSRAM) | ||
| JP2010013438A5 (ja) | 過剰増殖性疾患を治療するための新規な組成物 | |
| RU2009131065A (ru) | Новая композиция для лечения метаболического синдрома | |
| Rascol et al. | New treatments for levodopa‐induced motor complications | |
| Altman et al. | Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology | |
| JP6294889B2 (ja) | ウイルス疾患の処置におけるｍｅｋ阻害物質 | |
| ES2356093T3 (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol. | |
| JP2010529118A5 (OSRAM) | ||
| RU2009118960A (ru) | Комбинации ацетаминофена/ибуппрофена | |
| JP2005512995A5 (OSRAM) | ||
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| JP2012255026A5 (OSRAM) | ||
| JP2009541348A5 (OSRAM) | ||
| JP2013516488A (ja) | 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療 | |
| RU2009142937A (ru) | Тапентадол для лечения в связи с остеоартрозом | |
| TWI351950B (en) | Use of (halobenzyloxy) benzylamino-propanamides fo | |
| Yu et al. | Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters | |
| JP2011516544A5 (OSRAM) | ||
| JP7016907B2 (ja) | 樹脂酸フェニレフリン粒子の製造プロセス | |
| JP2006104186A (ja) | 感冒用医薬組成物 | |
| CL2013003176A1 (es) | Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol. | |
| UY28457A1 (es) | Nueva composición | |
| EP2034829A1 (en) | Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association | |
| JP2008531665A5 (OSRAM) | ||
| JP2005515199A5 (OSRAM) |